Opal Wealth Advisors LLC Sells 302 Shares of Zoetis Inc. $ZTS

Opal Wealth Advisors LLC lessened its stake in shares of Zoetis Inc. (NYSE:ZTS) by 25.1% during the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 903 shares of the company’s stock after selling 302 shares during the period. Opal Wealth Advisors LLC’s holdings in Zoetis were worth $141,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Portside Wealth Group LLC raised its position in Zoetis by 24.7% during the first quarter. Portside Wealth Group LLC now owns 33,709 shares of the company’s stock worth $5,550,000 after acquiring an additional 6,672 shares in the last quarter. Tandem Investment Advisors Inc. raised its position in Zoetis by 100.3% during the first quarter. Tandem Investment Advisors Inc. now owns 395,626 shares of the company’s stock worth $65,140,000 after acquiring an additional 198,089 shares in the last quarter. Flagship Harbor Advisors LLC raised its holdings in shares of Zoetis by 31.2% in the 1st quarter. Flagship Harbor Advisors LLC now owns 7,394 shares of the company’s stock valued at $1,217,000 after purchasing an additional 1,760 shares during the period. Horizon Financial Services LLC bought a new stake in shares of Zoetis in the 1st quarter valued at about $380,000. Finally, Soros Capital Management LLC raised its holdings in shares of Zoetis by 32.0% in the 1st quarter. Soros Capital Management LLC now owns 17,441 shares of the company’s stock valued at $2,872,000 after purchasing an additional 4,230 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Down 1.5%

NYSE ZTS opened at $142.43 on Wednesday. The business’s 50-day moving average price is $150.82 and its two-hundred day moving average price is $156.17. Zoetis Inc. has a 12 month low of $139.70 and a 12 month high of $197.51. The firm has a market capitalization of $63.12 billion, a PE ratio of 24.52, a price-to-earnings-growth ratio of 2.32 and a beta of 0.89. The company has a current ratio of 1.76, a quick ratio of 1.04 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last announced its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating the consensus estimate of $1.62 by $0.14. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.The business had revenue of $2.46 billion for the quarter, compared to analysts’ expectations of $2.41 billion. During the same period in the prior year, the business posted $1.56 earnings per share. The firm’s revenue was up 4.2% on a year-over-year basis. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, analysts expect that Zoetis Inc. will post 6.07 EPS for the current year.

Wall Street Analysts Forecast Growth

ZTS has been the topic of a number of research analyst reports. Stifel Nicolaus cut Zoetis from a “buy” rating to a “hold” rating and dropped their price target for the company from $165.00 to $160.00 in a research note on Wednesday, June 18th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. Piper Sandler raised their price objective on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research note on Monday, August 11th. Leerink Partners cut shares of Zoetis from an “outperform” rating to a “market perform” rating and decreased their price objective for the company from $180.00 to $155.00 in a research note on Thursday, July 17th. Finally, Argus reaffirmed a “buy” rating and set a $190.00 price target on shares of Zoetis in a report on Tuesday, September 9th. Five analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $200.88.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.